Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.65 USD | +2.40% | -4.05% | -16.47% |
Mar. 25 | Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction | MT |
Feb. 27 | Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024 |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 62% by 2026.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-16.47% | 644M | C- | ||
+72.92% | 12.38B | B- | ||
-19.68% | 7.92B | C+ | ||
+16.20% | 7.2B | C- | ||
+6.78% | 5.84B | B | ||
+7.49% | 5.07B | D+ | ||
+23.97% | 4.53B | - | ||
-19.61% | 3.88B | B- | ||
-41.54% | 2.23B | C | ||
+1.24% | 2.02B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TMCI Stock
- Ratings Treace Medical Concepts, Inc.